Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVN-492
- Development stage
- Preclinical
- Lead developer
- Avineuro Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AVN-492 is a novel, highly potent, and highly selective small molecule 5-HT6 receptor antagonist developed by Avineuro Pharmaceuticals for the treatment of central nervous system (CNS) diseases. It exhibits an exceptionally high affinity for the 5-HT6 receptor (Ki = 91 pM), showing over 1,000-fold selectivity over the 5-HT2B receptor. Preclinical evaluations in rodents have shown that AVN-492 possesses high oral bioavailability and excellent brain permeability. The compound is being investigated as a potential therapeutic for cognitive and neurodegenerative impairments associated with conditions such as Alzheimer's disease and schizophrenia, currently serving as a backup candidate in the company's pipeline.
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)HTR6 (5-hydroxytryptamine receptor 6)
Beyond the preview
Go deeper on AVN-492.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVN-492.